Belize is the only English-speaking country in Central America and a CARICOM member, positioning it as an early / exploratory option for sponsors seeking English-language operations near the US. Clinical research proceeds under Ministry of Health & Wellness oversight and institutional ethics review following ISO 14155. bioaccess® scopes the regulatory pathway per study — Belize is best suited to specific feasibility-driven programs rather than large multi-site trials.
Belize is a candid, emerging option in the LATAM/Caribbean clinical research landscape. It does not yet have an extensive clinical-trial-specific regulatory regime; studies proceed under the oversight of the Ministry of Health & Wellness pursuant to the Health Services Act (2016) and the Public Health Act, with institutional ethics review carried out under ISO 14155 and the Declaration of Helsinki.
What makes Belize distinctive is language and geography. It is the only English-speaking country in Central America and a CARICOM member, which simplifies protocol translation, informed consent, and investigator communication for US and UK-based sponsors. It is also proximate to major US medical hubs.
We position Belize honestly: it is best suited to specific, feasibility-driven programs — not as a country with a large, established multi-site network. bioaccess® implements ISO 14155-compliant oversight structures in partnership with the Ministry of Health & Wellness and institutional ethics boards to satisfy the FDA's human-subject-protection expectations under 21 CFR 812.28, and scopes feasibility and the regulatory pathway per program.
Clinical research in Belize is conducted under the oversight of the Ministry of Health & Wellness, pursuant to the Health Services Act (2016) and the Public Health Act. Because Belize does not yet have an extensive clinical-trial-specific regulatory regime, engagement with the Ministry is often case-by-case. bioaccess® coordinates directly with the Ministry and scopes the pathway per program.
Ethics oversight for clinical research in Belize is provided by institutional ethics committees following ISO 14155 and the Declaration of Helsinki. Committees review protocols for scientific merit, risk-benefit balance, informed consent adequacy, and patient protection. bioaccess® prepares ethics packages and manages committee interactions.
Belize is the only English-speaking country in Central America and a member of CARICOM. This eliminates translation requirements for protocol, informed consent, and site training materials for US and UK sponsors and simplifies communication with investigators and Ministry staff. It also positions Belize as a distinctive option within the Caribbean regulatory landscape.
Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Belize for IDE submissions and marketing applications, provided studies are conducted under ISO 14155 with appropriate Ministry of Health oversight and institutional ethics approval. bioaccess® designs every protocol for FDA submission from day one, with source data verification and monitoring practices built around 21 CFR expectations.
| Metric | Belize 🇧🇿 | United States 🇺🇸 | Europe (EU) 🇪🇺 |
|---|---|---|---|
| Regulatory oversight | Ministry of Health & Wellness (Health Services Act 2016) | 21 CFR 812 (IDE + IRB) | EU CTR/MDR |
| Clinical-trial framework maturity | Emerging / case-by-case | Established | Established |
| Ethics review | Institutional EC (ISO 14155 / Helsinki) | IRB | Per-country EC |
| Language | English (official) | English | Varies |
| FDA data acceptance | Eligible for submission/review — 21 CFR 812.28 (ISO 14155) | Native | Yes, with justification |
| Cost vs. US program | ~30% lower | Baseline | ~15–25% lower |
Regulatory details reflect published national frameworks; timelines and costs vary by device complexity, therapeutic area, and monitoring requirements. bioaccess® confirms the current pathway for each program.
Clinical research in Belize is conducted under the oversight of the Ministry of Health & Wellness, pursuant to the Health Services Act (2016) and the Public Health Act. Belize does not yet have an extensive clinical-trial-specific regulatory regime, so engagement is often case-by-case.
No. Belize is an emerging, exploratory option. It is best suited to specific, feasibility-driven programs rather than large multi-site trials. bioaccess® assesses feasibility and scopes the regulatory pathway per study.
English. Belize is the only English-speaking country in Central America and a CARICOM member, which eliminates the need to translate protocols, informed consent forms, and site training materials for US and UK sponsors.
Ethics oversight is provided by institutional ethics committees following ISO 14155 and the Declaration of Helsinki. bioaccess® prepares ethics packages and manages committee interactions.
Yes. Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Belize when studies are conducted under ISO 14155 with appropriate Ministry of Health oversight and institutional ethics approval. bioaccess® designs protocols for FDA submission from the start.
Belize is a strong fit for programs where English-language operations, Caribbean/CARICOM positioning, or feasibility exploration of an emerging market matter — for example, a targeted pilot or a study needing English site staff without translation overhead. bioaccess® confirms feasibility program by program.
All countries we serve · Contact bioaccess® · First-in-Human CRO